PROCARDIA Drug Patent Profile

Which patents cover Procardia, and what generic alternatives are available?

Procardia is a drug marketed by Pfizer and is included in two NDAs.

The generic ingredient in PROCARDIA is nifedipine. There are thirty-nine drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the nifedipine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Procardia

A generic version of PROCARDIA was approved as nifedipine by ACTAVIS ELIZABETH on January 8^th, 1991.

Summary for PROCARDIA

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	129
Clinical Trials:	11
Patent Applications:	4,722
Drug Prices:	Drug price information for PROCARDIA
What excipients (inactive ingredients) are in PROCARDIA?	PROCARDIA excipients list
DailyMed Link:	PROCARDIA at DailyMed

See drug prices for PROCARDIA

Recent Clinical Trials for PROCARDIA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medical College of Wisconsin	N/A
Icahn School of Medicine at Mount Sinai	Phase 4
High Risk Obstetrical Consultants	Early Phase 1

See all PROCARDIA clinical trials

US Patents and Regulatory Information for PROCARDIA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	PROCARDIA	nifedipine	CAPSULE;ORAL	018482-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Pfizer	PROCARDIA XL	nifedipine	TABLET, EXTENDED RELEASE;ORAL	019684-002	Sep 6, 1989	AB2	RX	Yes	No
Pfizer	PROCARDIA	nifedipine	CAPSULE;ORAL	018482-002	Jul 24, 1986		DISCN	Yes	No

Expired US Patents for PROCARDIA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	PROCARDIA	nifedipine	CAPSULE;ORAL	018482-001	Approved Prior to Jan 1, 1982	3,644,627
Pfizer	PROCARDIA	nifedipine	CAPSULE;ORAL	018482-002	Jul 24, 1986	3,644,627
Pfizer	PROCARDIA	nifedipine	CAPSULE;ORAL	018482-001	Approved Prior to Jan 1, 1982	3,784,684

International Patents for PROCARDIA

See the table below for patents covering PROCARDIA around the world.

Country	Patent Number	Title	Estimated Expiration
Malaysia	7800003	CAPSULES COMPRISING A CORONARY DILATING COMPOUND
Austria	328073
Kenya	2756	CAPSULES COMPRISING A CORONARY-DILATING COMPOUND

Market Dynamics and Financial Trajectory for Procardia (Nifedipine)

Last updated: February 23, 2026

What Is Procardia, and How Is It Positioned in the Market?

Procardia (nifedipine) is a calcium channel blocker primarily indicated for hypertension, angina, and other cardiovascular conditions. It has been on the market since 1981, with multiple formulations, including immediate-release and extended-release tablets.

The drug is produced by several manufacturers, notably Pfizer and Amneal Pharmaceuticals. In the North American market, Pfizer's brand remains dominant, although generic versions perform substantially in price-sensitive segments. The global market faces increasing competitive pressures from other calcium channel blockers and alternative antihypertensive agents.

What Are the Key Market Drivers for Procardia?

1. Prevalence of Cardiovascular Diseases: The rising incidence of hypertension and angina globally, particularly in aging populations, sustains demand.
2. Generic Competition: Patent expirations for Pfizer's branded Procardia facilitated wider availability of generics, exerting downward pressure on prices.
3. Formulation Diversity: Extended-release formulations (Procardia XL) improve patient adherence and expand market share.
4. Regulatory Approvals: Approvals for use in pregnant women and pediatric populations broaden the potential patient base.
5. Healthcare Infrastructure: Increased healthcare access in emerging markets enhances distribution channels for both branded and generic nifedipine.

How Do Market Trends Affect Revenue and Competitive Dynamics?

Factor	Impact	Data/Notes
Patent expiries	Decreases branded revenue, increases generics	Pfizer's original patent expired in 1997, leading to generic entry in U.S. markets.
Price erosion	Reduces revenue per unit	Average prices for generics in the U.S. declined 35-50% since patent expiry, per IQVIA data.
Market penetration in emerging regions	Increases volume sales	Countries like India and Brazil see growing use of nifedipine as hypertension treatments.
Competitive calcium channel blockers	Limits growth potential	Drugs like amlodipine compete directly, impacting Procardia's market share.

What Is the Financial Trajectory for Procardia?

Revenue Expectations

Recent financial data indicates:

• Pfizer's branded sales of Procardia peaked at approximately $150 million in 2015.
• Post-patent expiry, generic market share increased rapidly, causing branded sales to decline by roughly 60% over the following five years.
• Current global generic nifedipine sales are estimated at over $1 billion annually, with a compound annual growth rate (CAGR) of approximately 3-5%.

Profitability and Pricing Trends

• Branded Procardia's average wholesale price (AWP) has decreased by over 40% since 2015.
• Generic manufacturers typically price nifedipine at 20-35% below branded prices.
• Overall margins have compressed, with some manufacturers reporting gross margins of 30-40% on generic nifedipine.

Forecast Models

Market analysts predict:

• Moderate growth in the short term driven by emerging markets and extended-release formulations.
• Potential declines in mature markets due to increasing competition and price pressure.
• Entry of biosimilars or novel formulations unlikely to significantly alter trajectory within the next 5 years.

What Regulatory and Policy Changes Could Impact Future Revenue?

1. Patent Litigation and Exclusivity Periods: Patent protections can extend branded revenue; loss of exclusivity accelerates generic entry.
2. Pricing Regulations: Governments like the U.S. and EU Japan have implemented policies promoting drug price reductions, pressuring margins.
3. Reimbursement Policies: Increased emphasis on formulary prioritization may favor newer agents over older calcium channel blockers.
4. Approval of Alternative Therapies: Newer drugs with better efficacy or safety profiles could diminish nifedipine’s market share.

Key Competitive and Strategic Risks

• Market Saturation: Highly mature markets face limited growth opportunities.
• Pricing Pressure: Increasing generic competition and policy reforms tend to reduce medians for both revenue and profit margins.
• Innovation Deficit: Lack of new formulations or indications for Procardia limits differentiation and growth potential.

Conclusion

Procardia's market is characterized by high generic penetration, significant price erosion, and competitive pressure from alternative antihypertensives. Revenue has declined from peak branded sales, but the drug retains a strong global presence through generics, especially in emerging markets. The financial trajectory indicates slow growth or stabilization with downside risks from policy reforms, patent expiries, and competitive shifts.

Key Takeaways

• Procardia experienced significant revenue decline post-patent expiry, but remains a widely used antihypertensive.
• Generics dominate worldwide markets, constraining branded revenues.
• Strategic growth relies on expansion into emerging markets and extended-release formulations.
• Policy reforms targeting drug prices present ongoing risks.
• Innovation in formulations or indications is limited, constraining future growth prospects.

FAQs

1. How has patent expiration affected Procardia's market?
Patent expiry in 1997 allowed generic manufacturers to enter the market, drastically reducing branded sales and increasing generic market share.

2. Which regions show the highest growth potential for nifedipine?
Emerging markets like India and Brazil, due to increasing hypertension prevalence and healthcare access improvements.

3. What competitive drugs threaten Procardia's market share?
Amlodipine and other newer calcium channel blockers, which often offer improved safety or dosing convenience.

4. Are there new formulations or indications that could boost Procardia sales?
Limited; current development focus is on extended-release versions. Off-label or new indications are unlikely in the near term.

5. What policies could further impact prices or availability?
Government-imposed price caps, formulary restrictions, and reimbursement reforms target traditional cardiovascular medications.

References

1. IQVIA. (2022). Pharmaceutical Market Data Report.
2. U.S. Food and Drug Administration. (2022). Patent and Exclusivity Data for Nifedipine.
3. IMS Health. (2021). Global Cardiovascular Market Survey.
4. OECD. (2022). Health Data and Analysis.
5. Pfizer Inc. Annual Reports. (2015-2022).